Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 14 , ISSUE 1 ( January-June, 2024 ) > List of Articles


Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What's in the Name?

Shivaram P Singh, KC Sudhamshu, Prajna Anirvan, Ananta Shrestha, Mamun Al Mahtab

Keywords : Alcohol, Fatty liver disease, Nomenclature, Prevention, South Asia, Steatotic liver disease, Stigma

Citation Information : Singh SP, Sudhamshu K, Anirvan P, Shrestha A, Al Mahtab M. Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What's in the Name?. Euroasian J Hepatogastroenterol 2024; 14 (1):1-4.

DOI: 10.5005/jp-journals-10018-1424

License: CC BY-NC 4.0

Published Online: 12-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


PDF Share
  1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7(9):851–861. DOI: 10.1016/s2468-1253(22)00165-0.
  2. Wang D, Xu Y, Zhu Z, et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. Front Nutr 2022;9:1047129. DOI: 10.3389/fnut.2022.1047129.
  3. Chen H, Zhan Y, Zhang J, et al. The global, regional, and national burden and trends of NAFLD in 204 countries and territories: An analysis from global burden of disease 2019. JMIR Public Health Surveill 2022;8(12):e34809. DOI: 10.2196/34809.
  4. Blais P, Husain N, Kramer JR, et al. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015;110(1):10–14. DOI: 10.1038/ajg.2014.134.
  5. Alexander M, Loomis AK, Fairburn–Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med 2018;16(1):130. DOI: 10.1186/s12916-018-1103-x.
  6. Prasad M, Sarin SK, Chauhan V. Expanding public health responses to non-communicable diseases: The NAFLD model of India. Lancet Gastroenterol Hepatol 2023;8(11):969–970. DOI: 10.1016/s2468-1253(23)00312-6.
  7. Singh A, Dhaliwal AS, Singh S, et al. Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort. Dig Dis Sci 2020;65(4):978–986. DOI: 10.1007/s10620-019-05700-9.
  8. Sanyal AJ. Nonalcoholic fatty liver disease in the Indian subcontinent: A medical consequence of globalization? Indian J Gastroenterol 2001;20(6):215–216. PMID: 11817771.
  9. Singh SP, Nayak S, Swain M, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: A preliminary ultrasonographic survey. Trop Gastroenterol 2004;25(2):76–79. PMID: 15471321.
  10. Farrell GC, Wong VW-S, Chitturi S. NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013;10(5):307–318. DOI: 10.1038/nrgastro.2013.34.
  11. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metabol 2006;91(12):4753–4761. DOI: 10.1210/jc.2006-0587.
  12. Singh SP, Misra B, Kar SK, et al. Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: Is it different? Clin Res Hepatol Gastroenterol 2015;39(4):482–488. DOI: 10.1016/j.clinre.2014.08.014.
  13. Azam G, Alam S, Hasan SN, et al. Insulin resistance in nonalcoholic fatty liver disease: Experience from Bangladesh. Bangladesh Crit Care J 2016;4(2):86–91. DOI: 10.3329/bccj.v4i2.30022.
  14. Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 2022;76(5):1423–1437. DOI: 10.1002/hep.32499.
  15. Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999–2014.e1991. DOI: 10.1053/j.gastro.2019.11.312.
  16. Wells JC. The Evolutionary Biology of Human Body Fatness: Thrift and Control. Cambridge: Cambridge University Press, 2010.
  17. Papavramidou NS, Papavramidis ST, Christopoulou–Aletra H. Galen on obesity: Etiology, effects, and treatment. World J Surg 2004;28(6):631–635. DOI: 10.1007/s00268-004-7458-5.
  18. European Association for the Study of the Liver, American Association for the Study of Liver Diseases, Latin American Association for the Study of the Liver. A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD. J Hepatol 2023;79(1): 4–5. DOI: 10.1016/j.jhep.2023.05.003.
  19. Duseja A, Taneja S. Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Not only premature but also confusing. J Clin Exp Hepatol 2021;11(2):278–279. DOI: 10.1016/j.jceh.2020.08.002.
  20. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology 2021;73(3):1194–1198. DOI: 10.1002/hep.31420.
  21. Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol 2021;74(4):972–974. DOI: 10.1016/j.jhep.2020.10.015.
  22. Singh SP, Anirvan P, Butt AS, et al. NAFLD vs MAFLD: South Asian NAFLD patients don't favor name change. Euroasian J Hepatogastroenterol 2022;12(Suppl. 1):S1–S4. DOI: 10.5005/jp-journals-10018-1363.
  23. Singh SP, Duseja A, Mahtab MA, et al. INASL–SAASL consensus statements on NAFLD name change to MAFLD. J Clin Exp Hepatol 2023;13(3):518–522. DOI: 10.1016/j.jceh.2022.12.011.
  24. Bianco C, Romeo S, Petta S, et al. MAFLD vs NAFLD: Let the contest begin! Liver Int 2020;40(9):2079–2081. DOI: 10.1111/liv.14620.
  25. García–Compeán D, Jiménez–Rodríguez AR. NAFLD vs MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol 2022;27(6):100765. DOI: 10.1016/j.aohep.2022.100765.
  26. Hagström H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 2023;80(2):e76–e77. DOI: 10.1016/j.jhep.2023.08.026.
  27. Perazzo H, Pacheco AG, Griep RH, et al. Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J Hepatol 2024;80(2):e72–e74. DOI: 10.1016/j.jhep.2023.08.025.
  28. Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol 2024;80(2):e74–e76. DOI: 10.1016/j.jhep.2023.08.027.
  29. Emanuele E, Minoretti P. Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”. Hepatology 2024;79(1):E4. DOI: 10.1097/hep.0000000000000586.
  30. Newsome P, Rinella ME, Lazarus JV, et al. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with “Ludwig disease”. Hepatology 2024;79(1):E5–E6. DOI: 10.1097/hep.0000000000000587.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.